An anonymous director reports

CLEARMIND MEDICINE ANNOUNCES SHAREHOLDERS MEETING RESULTS

All of the matters put forward before shareholders for consideration and approval at Clearmind Medicine Inc.'s meeting held on Nov. 14, 2023, as set out in the company's management information circular dated Oct. 9, 2023, were approved by the requisite majority of votes cast at the meeting, including a resolution fixing the board of directors at four members, the election of directors of the company for the ensuing year, a resolution to establish and approve an omnibus equity incentive plan, and a resolution approving the directors to effect a consolidation of the common shares in the capital of the company on the basis of 50 preconsolidation shares for one postconsolidation share, or such other lesser consolidation ratio as determined by the company's board of directors at its sole discretion, in one or more tranches during the 12 months immediately following the meeting.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 15 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.